Our Fight against Cancer in the 21st Century
A special issue of Biology (ISSN 2079-7737). This special issue belongs to the section "Cancer Biology".
Deadline for manuscript submissions: closed (1 February 2024) | Viewed by 2675
Special Issue Editor
Interests: T cell immunology; T cell receptors; major histocompatibility complexes; glycoimmunology; synthetic biology; Siglecs
Special Issue Information
Dear Colleagues,
More than five decades later, cancer continues to haunt many of us. Despite new advances in immunotherapy, there is still little progress in treating certain types of cancer, e.g., solid tumors. Potential factors that can aggravate cancer progress need to be identified earlier and targetable for intervention. In this issue, an update on recent advances and breakthrough across different approaches such as biochemistry, genetics, immunology, microbiology and epidemiology in cancer diagnosis, prognosis and treatment will be covered. It will describe the current state-of-the-art approaches and emerging trends that can potentially monitor or even halt cancer progression.
Our earliest effort to find the leading causes of cancer can be traced back to President Nixon who signed the National Cancer Act back in the 1970s. More than five decades later, it is still regarded as a death sentence for many. While disease diagnosis and prognostic models have greatly improved, the solution to certain types of cancer still remains a highly complex process. Today, advances in methods in oncology range from whole exome sequencing, higher-plexed spatial immunoprofiling, stem cell therapy, targeted therapy, nanoparticles, chemodynamic therapy and emerging T cell therapeutics, with a focus on precision, safety and efficacy. This issue will present an update on recent advances and breakthroughs across different approaches in cancer diagnosis, prognosis and treatment.
To contribute to the Special Issue “Our Fight against Cancer in the 21st Century”, authors are invited to crosscut different topics not limited to biochemistry, genetics, immunology, microbiology and epidemiology that can greatly enrich our understanding in cancer occurrence, risk factors, progression and treatment options, providing the scientific community with the latest progress in our effort in cracking the cancer code using multidisciplinary approaches. It will describe the current state-of-the-art approaches for identifying factors that are most widely used, as well as selected methods in deciphering processes that can drive life-threatening cancer stages.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: biochemistry, genetics, immunology and microbiology.
Dr. Jackwee Lim
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- treatment
- diagnosis
- prognosis
- risk factors
- disease progression
- tumor survival
- tumor evasion